Steven R Ytterberg
Overview
Explore the profile of Steven R Ytterberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
5378
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cronholm P, Applequist J, Krischer J, Fontenot E, Davis T, Burroughs C, et al.
BMC Med Res Methodol
. 2024 Oct;
24(1):244.
PMID: 39425055
Background: Traditional medical research infrastructures relying on the Centers of Excellence (CoE) model (an infrastructure or shared facility providing high standards of research excellence and resources to advance scientific knowledge)...
2.
Charles-Schoeman C, Fleischmann R, Mysler E, Greenwald M, Ytterberg S, Koch G, et al.
Arthritis Rheumatol
. 2024 Mar;
76(8):1218-1229.
PMID: 38481002
Objective: The ORAL Surveillance trial found a dose-dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events with tofacitinib versus tumor necrosis factor inhibitors (TNFi). We aimed to assess...
3.
Szekanecz Z, Buch M, Charles-Schoeman C, Galloway J, Karpouzas G, Kristensen L, et al.
Nat Rev Rheumatol
. 2024 Feb;
20(3):196.
PMID: 38302658
No abstract available.
4.
Szekanecz Z, Buch M, Charles-Schoeman C, Galloway J, Karpouzas G, Kristensen L, et al.
Nat Rev Rheumatol
. 2024 Jan;
20(2):101-115.
PMID: 38216757
Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, upadacitinib and filgotinib, are increasingly used in the treatment of rheumatoid arthritis (RA). There has been debate about their safety, particularly following the...
5.
Karpouzas G, Szekanecz Z, Baecklund E, Mikuls T, Bhatt D, Wang C, et al.
Ther Adv Musculoskelet Dis
. 2023 Nov;
15:1759720X231201047.
PMID: 37942277
Background: In patients with rheumatoid arthritis (RA), persistent inflammation and increasing disease activity are associated with increased risk of adverse events (AEs). Objectives: To assess relationships between RA disease activity...
6.
Dougados M, Charles-Schoeman C, Szekanecz Z, Giles J, Ytterberg S, Bhatt D, et al.
Ann Rheum Dis
. 2023 Jan;
82(4):575-577.
PMID: 36720582
No abstract available.
7.
Casal Moura M, Thompson G, Nelson D, Fussner L, Hummel A, Jenne D, et al.
Arthritis Rheumatol
. 2022 Dec;
75(5):748-759.
PMID: 36515151
Objective: Proteinase 3 (PR3) is the major antigen for antineutrophil cytoplasmic antibodies (ANCAs) in the systemic autoimmune vasculitis, granulomatosis with polyangiitis (GPA). PR3-targeting ANCAs (PR3-ANCAs) recognize different epitopes on PR3....
8.
Charles-Schoeman C, Buch M, Dougados M, Bhatt D, Giles J, Ytterberg S, et al.
Ann Rheum Dis
. 2022 Sep;
82(1):119-129.
PMID: 36137735
Objectives: Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) with or without a history of atherosclerotic...
9.
Gamerith G, Mildner F, Merkel P, Harris K, Cooney L, Lim N, et al.
Ann Rheum Dis
. 2022 Aug;
82(2):253-261.
PMID: 35973802
Objectives: We investigated whether soluble immune checkpoints (sICPs) predict treatment resistance, relapse and infections in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). Methods: Plasma sICP concentrations from available samples...
10.
Ytterberg S, Bhatt D, Connell C
N Engl J Med
. 2022 May;
386(18):1768.
PMID: 35507493
No abstract available.